🇺🇸 American Board of Internal Medicine Certification (ABIM Board Certification) · subject

American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease Syllabus

The Cardiovascular Disease syllabus for American Board of Internal Medicine Certification (ABIM Board Certification) in full: 5 chapters, 22 topics and 16 sub-topics, every one listed below, plus 61 Cardiovascular Disease flashcards with answers.

5Chapters
22Topics
16Sub-topics
61Flashcards

Cardiovascular Disease syllabus: all 5 chapters

Expand any chapter to see its topics and sub-topics.

  1. Ischemic Heart Disease & Acute Coronary Syndromes

    4 topics
    • Stable Ischemic Heart Disease
      • Chronic stable angina assessment and risk stratification
      • Pretest probability and noninvasive testing selection
      • Optimal medical therapy and indications for revascularization
    • Acute Coronary Syndromes
      • STEMI recognition and reperfusion strategy
      • NSTEMI/unstable angina risk scores (TIMI, GRACE)
      • Antiplatelet and anticoagulation regimens
    • Secondary Prevention
      • Statin and lipid-lowering targets
      • Cardiac rehabilitation and lifestyle modification
    • Mechanical and ischemic complications of MI
  2. Heart Failure & Cardiomyopathies

    4 topics
    • HFrEF: guideline-directed medical therapy
      • ARNI, beta-blockers, MRA, SGLT2 inhibitors
      • Device therapy (ICD, CRT) indications
    • HFpEF diagnosis and management
    • Acute decompensated heart failure and cardiogenic shock
    • Cardiomyopathies
      • Dilated, hypertrophic, restrictive phenotypes
      • Infiltrative disease (amyloid, sarcoid, hemochromatosis)
  3. Arrhythmias & Conduction Disorders

    5 topics
    • Atrial fibrillation and flutter
      • Rate vs rhythm control
      • CHA2DS2-VASc and anticoagulation decisions
    • Supraventricular tachycardias
    • Ventricular arrhythmias and sudden cardiac death prevention
    • Bradyarrhythmias and pacing indications
    • Long QT and inherited channelopathies
  4. Valvular & Structural Heart Disease

    4 topics
    • Aortic stenosis and regurgitation
      • Severity grading by echocardiography
      • Timing of valve replacement (SAVR vs TAVR)
    • Mitral valve disease
    • Infective endocarditis diagnosis and management
    • Prosthetic valve evaluation and anticoagulation
  5. Vascular Disease & Hypertension

    5 topics
    • Hypertension diagnosis, staging, and pharmacotherapy
    • Secondary hypertension workup
    • Aortic aneurysm and dissection
    • Peripheral arterial disease
    • Pericardial disease and tamponade

American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease flashcards — 61 questions with answers

  1. In stable ischemic heart disease, which two classes of medications are proven to reduce mortality/cardiovascular events (not just symptoms)?

    Aspirin (antiplatelet) and high-intensity statins reduce events. Beta-blockers, nitrates, ranolazine, and calcium channel blockers are primarily antianginal/symptomatic. ACE inhibitors/ARBs reduce events in those with LV dysfunction, diabetes, HTN, or CKD.

  2. When is revascularization (vs optimal medical therapy alone) indicated to improve survival in stable ischemic heart disease?

    Survival benefit is established for: left main disease (>=50% stenosis), multivessel disease with reduced LVEF, and proximal LAD disease. Per ISCHEMIA trial, in stable patients with moderate-severe ischemia but preserved EF and no left main disease, routine revascularization does not reduce death/MI over OMT.

  3. What ECG and biomarker findings distinguish unstable angina from NSTEMI?

    Both have ischemic symptoms without ST elevation (may show ST depression or T-wave inversion). Unstable angina has NEGATIVE troponin; NSTEMI has ELEVATED (positive) troponin indicating myocardial necrosis.

  4. What is the immediate management priority for a STEMI, and what are the target reperfusion times?

    Emergent reperfusion. Primary PCI is preferred with goal door-to-balloon <=90 min (or <=120 min if transfer needed). If PCI unavailable within 120 min, give fibrinolytics within 30 min of arrival (door-to-needle), then transfer for PCI.

  5. In acute coronary syndrome, when should supplemental oxygen be administered?

    Only when oxygen saturation is <90% (or <94% by some guidelines) or the patient has respiratory distress. Routine oxygen in normoxemic patients provides no benefit and may be harmful.

  6. What is the standard dual antiplatelet therapy (DAPT) duration after drug-eluting stent placement for ACS?

    Aspirin indefinitely plus a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) for at least 12 months. Duration may be shortened for high bleeding risk or extended for high ischemic risk.

  7. Why is prasugrel contraindicated in patients with prior stroke or TIA?

    Prasugrel increases the risk of intracranial and major bleeding; in patients with prior stroke/TIA it causes net harm. It is also generally avoided in patients >=75 years or <60 kg.

  8. List the five core components of secondary prevention after myocardial infarction.

    1) High-intensity statin (LDL goal <70, often <55 mg/dL); 2) Antiplatelet therapy (aspirin +/- P2Y12); 3) Beta-blocker; 4) ACE inhibitor/ARB (especially if EF reduced, HTN, DM, CKD); 5) Lifestyle: smoking cessation, cardiac rehab, diet, exercise, BP/glucose control.

  9. Which non-statin lipid-lowering agents are added for secondary prevention when LDL remains above goal on maximal statin therapy?

    Ezetimibe first (oral), then a PCSK9 inhibitor (evolocumab/alirocumab) for very high-risk patients. Bempedoic acid and inclisiran are additional options.

  10. A patient develops a new harsh holosystolic murmur and acute pulmonary edema 3-5 days after an MI. What two mechanical complications must be distinguished, and how?

    Ventricular septal rupture vs acute mitral regurgitation (papillary muscle rupture). Distinguish by echocardiography; a right heart catheter shows an oxygen 'step-up' in the RV with VSR but a prominent v-wave (PCWP) with acute MR. Both require emergent surgery.

  11. What is the typical timing and presentation of free wall rupture after acute MI?

    Occurs days 1-7 (peak 3-5 days), more common in first transmural MI, elderly, women, and late reperfusion. Presents as sudden hemodynamic collapse, pulseless electrical activity, and cardiac tamponade. Usually fatal; requires emergent pericardiocentesis and surgery.

  12. Which artery occlusion classically causes right ventricular infarction, and how does management differ?

    Proximal right coronary artery (RCA). RV infarction causes hypotension with clear lungs and elevated JVP; it is preload-dependent. Treat with IV fluids; AVOID nitrates and diuretics, which reduce preload and worsen hypotension.

  13. What ECG lead set should be obtained when inferior STEMI is present, and what does it detect?

    Right-sided leads (especially V4R) to detect RV infarction, and posterior leads (V7-V9) to detect posterior MI. ST elevation in V4R indicates RV involvement.

  14. List the four pillars (drug classes) of guideline-directed medical therapy for HFrEF.

    1) ARNI (sacubitril/valsartan) or ACEi/ARB; 2) Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol); 3) Mineralocorticoid receptor antagonist (spironolactone/eplerenone); 4) SGLT2 inhibitor (dapagliflozin/empagliflozin).

  15. What washout period is required when switching from an ACE inhibitor to an ARNI (sacubitril/valsartan), and why?

    A 36-hour washout from the ACE inhibitor is required to avoid overlapping neprilysin and ACE inhibition, which markedly increases angioedema risk.

  16. In HFrEF, when is an implantable cardioverter-defibrillator (ICD) indicated for primary prevention?

    LVEF <=35% despite >=3 months of optimal GDMT, NYHA class II-III (or class I if EF <=30% ischemic), with reasonable expectation of survival >1 year. For nonischemic cardiomyopathy, wait 3 months on GDMT; for post-MI, wait at least 40 days.

  17. What are the indications for cardiac resynchronization therapy (CRT) in HFrEF?

    LVEF <=35%, sinus rhythm, LBBB with QRS >=150 ms, and NYHA class II-IV symptoms on GDMT. Greatest benefit with LBBB and QRS >=150 ms; benefit is less for non-LBBB or QRS 120-149 ms.

  18. Which additional HFrEF therapies are indicated specifically in self-identified Black patients and in those with persistent symptoms?

    Hydralazine plus isosorbide dinitrate added to GDMT improves outcomes in Black patients with NYHA III-IV. Ivabradine is added for sinus rhythm with heart rate >=70 despite maximal beta-blocker.

  19. What diagnostic score/criteria support a diagnosis of HFpEF in a patient with dyspnea and preserved EF?

    HFpEF requires EF >=50%, evidence of elevated filling pressures, and structural/functional abnormalities. The H2FPEF and HFA-PEFF scores incorporate obesity, atrial fibrillation, age, pulmonary hypertension, elevated filling pressures, and echo findings (e.g., E/e', LA enlargement, elevated NT-proBNP).

  20. Which drug class has the strongest evidence for reducing heart failure hospitalizations in HFpEF?

    SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalizations across the full EF spectrum, including HFpEF. Management also targets comorbidities: BP control, diuretics for congestion, AF management, and weight loss.

Show the other 41 Cardiovascular Disease flashcards
  1. What is the recommended first-line treatment for symptomatic congestion in acute decompensated heart failure?

    IV loop diuretics (e.g., furosemide), typically at >=2.5x the home oral dose, given as bolus or continuous infusion. Add vasodilators (nitroglycerin) for hypertensive pulmonary edema if BP allows.

  2. Describe the four clinical hemodynamic profiles used to classify acute heart failure (Stevenson/Forrester).

    Based on congestion (wet/dry) and perfusion (warm/cold): Warm-dry (A, compensated), Warm-wet (B, congested but perfused - diurese/vasodilate), Cold-wet (C, congested and hypoperfused - inotropes +/- diuretics), Cold-dry (L, hypoperfused, not congested - cautious fluids/inotropes).

  3. What defines cardiogenic shock hemodynamically?

    Sustained hypotension (SBP <90 mmHg for >=30 min or need for vasopressors), with evidence of end-organ hypoperfusion, cardiac index <2.2 L/min/m2, and elevated PCWP >15 mmHg, in the setting of adequate or elevated filling pressures.

  4. What is the most common cause of cardiogenic shock, and what is the cornerstone of treatment?

    Acute MI with LV pump failure is the most common cause. Cornerstone is emergent revascularization (PCI) of the culprit lesion (per SHOCK trial), plus hemodynamic support with inotropes/vasopressors and mechanical support (IABP, Impella, ECMO) as needed.

  5. What is the diagnostic finding and triggers for Takotsubo (stress) cardiomyopathy?

    Apical ballooning (akinesis of mid/apical LV with basal hyperkinesis) on imaging, often after intense emotional or physical stress, mimicking ACS with chest pain and ST changes but non-obstructive coronaries. Usually reversible over weeks.

  6. What is the classic echocardiographic and physiologic finding distinguishing hypertrophic obstructive cardiomyopathy (HOCM)?

    Asymmetric septal hypertrophy with systolic anterior motion (SAM) of the mitral valve and dynamic LV outflow tract obstruction. The murmur INCREASES with maneuvers that decrease preload/afterload (Valsalva, standing) and DECREASES with squatting/handgrip.

  7. How do you distinguish restrictive cardiomyopathy from constrictive pericarditis?

    Constriction: pericardial thickening/calcification, ventricular interdependence (respiratory variation in mitral/tricuspid inflow), septal bounce, equalization of diastolic pressures - treated surgically. Restriction: biatrial enlargement, high BNP, no respiratory variation; often from infiltration (amyloid). Cardiac MRI and invasive hemodynamics help differentiate.

  8. What is the CHA2DS2-VASc score and its use in atrial fibrillation?

    Stroke risk score: Congestive HF (1), Hypertension (1), Age >=75 (2), Diabetes (1), Stroke/TIA/thromboembolism (2), Vascular disease (1), Age 65-74 (1), Sex category female (1). Anticoagulation is recommended for men with score >=2 and women >=3; consider for score of 1.

  9. In atrial fibrillation, which anticoagulants are preferred and when must warfarin be used instead of DOACs?

    DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF. Warfarin is required for AF with moderate-to-severe mitral stenosis or a mechanical prosthetic valve, where DOACs are contraindicated.

  10. What does the AFFIRM/RACE trial evidence say about rate vs rhythm control in atrial fibrillation, and what does EAST-AFNET 4 add?

    Older trials (AFFIRM) showed no mortality difference between rate and rhythm control. EAST-AFNET 4 showed early rhythm control (within 1 year of diagnosis) reduces cardiovascular outcomes. Anticoagulation must continue regardless of rhythm strategy based on CHA2DS2-VASc.

  11. What is the characteristic ECG appearance of typical atrial flutter and its preferred curative treatment?

    Sawtooth flutter waves, classically negative in inferior leads (II, III, aVF), with atrial rate ~300 bpm and often 2:1 AV conduction (ventricular rate ~150). Cavotricuspid isthmus ablation is highly effective and curative for typical (counterclockwise) flutter.

  12. How do you acutely manage a stable patient with AVNRT (regular narrow-complex SVT)?

    First vagal maneuvers (Valsalva, modified Valsalva, carotid sinus massage). If unsuccessful, IV adenosine (6 mg then 12 mg). Alternatives: IV diltiazem/verapamil or beta-blockers. If hemodynamically unstable, synchronized cardioversion.

  13. In Wolff-Parkinson-White syndrome with atrial fibrillation, which AV nodal blocking agents must be AVOIDED and why?

    Avoid AV nodal blockers (adenosine, beta-blockers, calcium channel blockers, digoxin) - they can accelerate conduction down the accessory pathway, causing rapid ventricular response and VF. Use procainamide or ibutilide, or synchronized cardioversion if unstable.

  14. What ECG finding is diagnostic of WPW in sinus rhythm?

    A short PR interval (<120 ms) and a delta wave (slurred upstroke of the QRS) with a widened QRS, reflecting pre-excitation through an accessory pathway.

  15. What criteria favor ventricular tachycardia over SVT with aberrancy in a wide-complex tachycardia?

    AV dissociation, capture/fusion beats, very wide QRS (>140 ms in RBBB pattern), extreme axis (northwest), concordance across precordial leads, and a history of structural heart disease/prior MI. When in doubt, treat wide-complex tachycardia as VT.

  16. What are the indications for a primary prevention ICD in nonischemic and ischemic cardiomyopathy?

    Ischemic: LVEF <=30% (or <=35% with NYHA II-III), >=40 days post-MI on GDMT. Nonischemic: LVEF <=35%, NYHA II-III, on >=3 months GDMT. Survival expectation >1 year. Secondary prevention: ICD after survived cardiac arrest or sustained VT with structural disease.

  17. What is the acute management of sustained ventricular tachycardia in a pulseless patient vs a stable patient?

    Pulseless VT/VF: immediate defibrillation (unsynchronized) and CPR per ACLS, with epinephrine and amiodarone. Stable monomorphic VT: IV antiarrhythmics (amiodarone, procainamide, or lidocaine) or synchronized cardioversion. Unstable with pulse: synchronized cardioversion.

  18. What is the management of polymorphic VT (torsades de pointes) associated with a long QT?

    IV magnesium sulfate is first-line. Correct electrolytes (K, Mg), stop QT-prolonging drugs, and increase heart rate via overdrive pacing or isoproterenol to shorten the QT. Defibrillate if pulseless/unstable.

  19. Differentiate the triggers for the major congenital long QT syndrome subtypes.

    LQT1 (KCNQ1, IKs): events with exercise, especially swimming. LQT2 (KCNH2/hERG, IKr): events with emotional stress or auditory stimuli (alarm). LQT3 (SCN5A, late sodium current): events during sleep/rest/bradycardia. Beta-blockers are mainstay (most effective in LQT1).

  20. What is the characteristic ECG pattern of Brugada syndrome, and how are events prevented?

    Coved-type ST-segment elevation (>=2 mm) with T-wave inversion in right precordial leads (V1-V2) - type 1 Brugada pattern. Risk of polymorphic VT/sudden death, often during sleep or fever. ICD for symptomatic/high-risk patients; avoid sodium channel blockers and treat fevers aggressively.

  21. What inherited arrhythmia is triggered by catecholamines/exercise and shows bidirectional VT, and how is it managed?

    Catecholaminergic polymorphic VT (CPVT), commonly from RYR2 mutations. Exercise/stress provokes bidirectional or polymorphic VT with a structurally normal heart. Treated with beta-blockers (nadolol), flecainide, exercise restriction, and ICD if needed.

  22. What are the indications for permanent pacing in bradyarrhythmias?

    Symptomatic sinus node dysfunction; symptomatic or high-grade AV block; complete (third-degree) AV block; Mobitz type II second-degree AV block; symptomatic Mobitz I; and AF with symptomatic bradycardia/pauses. Pace for the conduction disease, not asymptomatic reversible causes.

  23. How do you distinguish Mobitz type I (Wenckebach) from Mobitz type II second-degree AV block, and which is more dangerous?

    Mobitz I: progressive PR prolongation until a dropped beat (block in AV node, usually benign). Mobitz II: constant PR with sudden dropped beats (block in His-Purkinje system, often wide QRS), high risk of progression to complete block - requires pacing.

  24. What echocardiographic criteria define severe aortic stenosis?

    Aortic valve area <1.0 cm2 (or <0.6 cm2/m2 indexed), mean transvalvular gradient >=40 mmHg, and peak aortic jet velocity >=4 m/s. 'Low-flow low-gradient' severe AS may have low gradients despite small valve area; dobutamine echo helps clarify.

  25. When is aortic valve replacement (AVR) indicated in aortic stenosis?

    Symptomatic severe AS (angina, syncope, dyspnea/HF); asymptomatic severe AS with LVEF <50%; severe AS undergoing other cardiac surgery; and select asymptomatic very severe AS or abnormal exercise testing. Choice of TAVR vs SAVR depends on surgical risk and anatomy.

  26. What are the key features and management of acute vs chronic aortic regurgitation?

    Acute AR (e.g., endocarditis, dissection): sudden severe pulmonary edema, tachycardia, NO time for LV dilation, soft S1 - surgical emergency. Chronic AR: gradual LV dilation, wide pulse pressure, water-hammer pulse, decrescendo diastolic murmur; surgery for symptoms, LVEF <=55%, or LV end-systolic dimension >50 mm.

  27. What distinguishes the murmurs and management of mitral stenosis vs mitral regurgitation?

    MS: opening snap with low-pitched diastolic rumble at apex; usually rheumatic; treat with rate control, anticoagulation if AF, and percutaneous balloon valvuloplasty for symptomatic moderate-severe pliable valves. MR: holosystolic murmur radiating to axilla; surgery/repair for severe symptomatic MR or LVEF 30-60% or LVESD >=40 mm.

  28. What are the modified Duke criteria for diagnosing infective endocarditis?

    Major: typical organism in 2 separate blood cultures (or persistent bacteremia) and endocardial involvement (vegetation/abscess/new regurgitation on echo). Minor: predisposing condition, fever >=38C, vascular phenomena, immunologic phenomena, suggestive microbiology. Definite IE = 2 major, or 1 major + 3 minor, or 5 minor.

  29. What are the major indications for surgery in infective endocarditis?

    Heart failure from valve dysfunction; uncontrolled/persistent infection or perivalvular abscess; difficult organisms (fungal, multidrug-resistant); recurrent emboli or large mobile vegetation (>10 mm) despite appropriate antibiotics; and prosthetic valve endocarditis with complications.

  30. Which cardiac conditions warrant antibiotic prophylaxis before high-risk dental procedures?

    Prosthetic heart valves (including TAVR) or prosthetic material for repair; prior infective endocarditis; unrepaired cyanotic congenital heart disease (or repaired with residual defects); and cardiac transplant recipients with valvulopathy. Standard regimen is amoxicillin 2 g PO 30-60 min before the procedure.

  31. What is the recommended anticoagulation and target INR for mechanical prosthetic heart valves?

    Lifelong warfarin (DOACs are contraindicated). Mechanical aortic valve: INR 2.5 (range 2.0-3.0). Mechanical mitral valve or any valve with added risk factors: INR 3.0 (range 2.5-3.5). Low-dose aspirin is added. Bioprosthetic valves typically need only short-term anticoagulation or antiplatelet therapy.

  32. How is hypertension staged per the 2017 ACC/AHA guideline?

    Normal <120/<80; Elevated 120-129/<80; Stage 1 HTN 130-139 or 80-89; Stage 2 HTN >=140 or >=90. Diagnosis requires proper out-of-office or repeated measurements. Hypertensive crisis is >=180/>=120.

  33. What are the recommended first-line antihypertensive drug classes, and which is preferred in Black patients without HF/CKD?

    First-line: thiazide diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers. In Black patients without heart failure or CKD, a thiazide diuretic or calcium channel blocker is preferred for initial monotherapy over ACEi/ARB.

  34. What clinical clues should prompt a workup for secondary hypertension?

    Resistant HTN (uncontrolled on 3 drugs including a diuretic), onset <30 or sudden onset, severe/malignant HTN, abrupt loss of control, hypokalemia, abdominal bruit, or target-organ damage out of proportion. Common causes: primary aldosteronism, renovascular disease, OSA, pheochromocytoma, renal parenchymal disease.

  35. What is the screening test for primary aldosteronism, the most common secondary cause of hypertension?

    Plasma aldosterone-to-renin ratio (ARR); an elevated aldosterone with suppressed renin is suggestive. Confirm with salt loading/saline suppression testing, then adrenal CT and adrenal vein sampling to localize before considering adrenalectomy.

  36. Compare the presentation and immediate management of Stanford type A vs type B aortic dissection.

    Type A involves the ascending aorta - surgical emergency (risk of tamponade, AR, coronary/cerebral malperfusion). Type B is distal to the left subclavian - managed medically with rapid IV beta-blockade (e.g., esmolol/labetalol) to lower heart rate and BP, surgery/endovascular for complications (malperfusion, rupture).

  37. What are the size thresholds for elective repair of an abdominal aortic aneurysm (AAA)?

    Repair when AAA diameter >=5.5 cm in men (>=5.0 cm in women), rapid growth (>0.5 cm in 6 months or >1 cm/year), or symptomatic/tender aneurysm. One-time ultrasound screening is recommended for men aged 65-75 who have ever smoked.

  38. What is the ankle-brachial index (ABI), and how do values classify peripheral arterial disease?

    ABI = highest ankle systolic pressure / highest brachial systolic pressure. Normal 1.0-1.4; borderline 0.91-0.99; PAD <=0.90; severe ischemia <0.40. ABI >1.40 suggests noncompressible, calcified vessels (common in diabetes/CKD).

  39. What is the medical management of symptomatic peripheral arterial disease (claudication)?

    Risk factor modification (smoking cessation is essential), high-intensity statin, antiplatelet therapy (aspirin or clopidogrel), control of HTN/diabetes, supervised exercise therapy, and cilostazol for claudication symptoms. Low-dose rivaroxaban plus aspirin reduces limb/cardiovascular events. Revascularization for lifestyle-limiting or critical limb ischemia.

  40. What are the classic ECG and physical exam findings of acute pericarditis?

    Diffuse concave-upward ST elevation with PR-segment depression (and PR elevation in aVR); a pericardial friction rub; pleuritic chest pain that improves leaning forward. Treatment is NSAIDs plus colchicine (colchicine reduces recurrence).

  41. What is Beck's triad and the hemodynamic hallmark of cardiac tamponade?

    Beck's triad: hypotension, muffled heart sounds, and elevated JVP (distended neck veins). The hallmark is pulsus paradoxus (>10 mmHg drop in systolic BP on inspiration) with echo showing diastolic RV/RA collapse. Treatment is urgent pericardiocentesis.

American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease FAQ

What is in the American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease syllabus?

American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease is split into 5 chapters: Ischemic Heart Disease & Acute Coronary Syndromes, Heart Failure & Cardiomyopathies, Arrhythmias & Conduction Disorders, Valvular & Structural Heart Disease and Vascular Disease & Hypertension. Together they contain 22 topics and 16 sub-topics.

How many chapters are in American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease?

5 chapters, containing 22 topics and 16 sub-topics. The largest chapter is Arrhythmias & Conduction Disorders, with 5 topics.

Are there flashcards for American Board of Internal Medicine Certification (ABIM Board Certification) Cardiovascular Disease?

Yes — a 61-card Cardiovascular Disease deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.